Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Centre of Orthopedic and Regenerative Medicine Research (CORE), Center for Interdisciplinary Research and Innovation (CIRI), Aristotle University of Thessaloniki, Thessaloniki, Greece.
Calcif Tissue Int. 2020 Nov;107(5):453-463. doi: 10.1007/s00223-020-00742-y. Epub 2020 Aug 9.
Diabetes mellitus (DM) is associated with an increased risk of fractures, mainly due to impaired bone architecture and microvascular complications. Whether DM is also associated with increased risk of sarcopenia is not yet known, with studies yielding inconclusive results. The aim of this study was to systematically review and synthesize the best available evidence regarding the association between DM and sarcopenia risk. A comprehensive search was conducted in PubMed, CENTRAL and Scopus databases. Data are expressed as odds ratio (OR) with 95% confidence intervals (CI). The I index was employed for heterogeneity. Only studies which had implemented at least two of the three criteria for sarcopenia diagnosis (low muscle mass, muscle strength and/or muscle performance), as defined by the international studying groups, were included. Fifteen studies fulfilled eligibility criteria, yielding a total of 1832 patients with type 2 DM (T2DM) and 1159 cases of sarcopenia. Patients with T2DM demonstrated a higher risk of sarcopenia compared with euglycemic subjects (OR 1.55, 95% CI 1.25-1.91, p < 0.001; I 34.6%). This risk remained significant when analysis was restricted to studies matched for age and sex. Sarcopenia risk was independent of disease definition or study design. Notably, T2DM patients presented lower muscle performance and strength compared with euglycemic subjects, whereas no difference in muscle mass was observed between groups. Patients with T2DM have an increased risk of sarcopenia compared with euglycemic subjects.
糖尿病(DM)与骨折风险增加相关,主要是由于骨结构受损和微血管并发症。然而,DM 是否也与肌少症风险增加相关尚不清楚,研究结果尚无定论。本研究旨在系统地回顾和综合关于 DM 和肌少症风险之间关联的最佳现有证据。在 PubMed、CENTRAL 和 Scopus 数据库中进行了全面搜索。数据表示为比值比(OR)和 95%置信区间(CI)。采用 I 指数评估异质性。仅纳入了至少实施了国际研究组定义的肌少症诊断的三个标准中的两个标准(低肌肉量、肌肉力量和/或肌肉功能)的研究。符合入选标准的研究共有 15 项,共纳入 1832 例 2 型糖尿病(T2DM)患者和 1159 例肌少症患者。与血糖正常的受试者相比,T2DM 患者发生肌少症的风险更高(OR 1.55,95%CI 1.25-1.91,p<0.001;I 34.6%)。当分析仅限于年龄和性别匹配的研究时,这种风险仍然显著。肌少症风险与疾病定义或研究设计无关。值得注意的是,与血糖正常的受试者相比,T2DM 患者的肌肉功能和力量较低,而两组之间的肌肉量无差异。与血糖正常的受试者相比,T2DM 患者发生肌少症的风险增加。